We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

21 hedge funds and large institutions have $118K invested in Moleculin Biotech in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.31% less ownership

Funds ownership: 0.42% → 0.11% (-0.31%)

5% less funds holding

Funds holding: 22 → 21 (-1)

92% less capital invested

Capital invested by funds: $1.44M → $118K (-$1.32M)

Holders
21
Holders Change
-1
Holders Change %
-4.55%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$67.6K
2
XT
XTX Topco
Cayman Islands
+$51.4K
3
VF
Virtu Financial
New York
+$48.6K
4
LPL Financial
LPL Financial
California
+$8.2K
5
UBS Group
UBS Group
Switzerland
+$6.56K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.22M
2
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
-$68.2K
3
Barclays
Barclays
United Kingdom
-$335
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$33
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
1
Citigroup
New York
$25.7K +$67.6K +3,299 +2,946%
XT
2
XTX Topco
Cayman Islands
$22.4K +$51.4K +2,506 +541%
VF
3
Virtu Financial
New York
$18K +$48.6K +2,371 New
LPL Financial
4
LPL Financial
California
$16.9K +$8.2K +400 +22%
Vanguard Group
5
Vanguard Group
Pennsylvania
$9.34K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$8.31K +$1.21K +59 +6%
Cambridge Investment Research Advisors
7
Cambridge Investment Research Advisors
Iowa
$4K – – –
BlackRock
8
BlackRock
New York
$3.74K – – –
Truist Financial
9
Truist Financial
North Carolina
$3.17K – – –
UBS Group
10
UBS Group
Switzerland
$2.41K +$6.56K +320 New
TRCT
11
Tower Research Capital (TRC)
New York
$1.18K +$2.11K +103 +191%
SHIM
12
Stone House Investment Management
Pennsylvania
$996 +$2.71K +132 New
NFSG
13
Newbridge Financial Services Group
Florida
$866 +$1.23K +60 +109%
Morgan Stanley
14
Morgan Stanley
New York
$280 – – –
SS
15
SBI Securities
Japan
$225 – – –
AUB
16
Atlantic Union Bankshares
Virginia
$115 +$308 +15 New
BWL
17
Bogart Wealth LLC
Virginia
$91 – – –
Bank of America
18
Bank of America
North Carolina
$44 +$103 +5 +500%
Osaic Holdings
19
Osaic Holdings
Arizona
$12 – – –
CFO
20
CVA Family Office
Colorado
$10 – – –
NSIM
21
North Star Investment Management
Illinois
$5 – – –
AC
22
Armistice Capital
New York
– -$1.22M -50,000 Closed
Cetera Investment Advisers
23
Cetera Investment Advisers
Illinois
– -$68.2K -2,800 Closed
Barclays
24
Barclays
United Kingdom
– -$335 -14 Closed
Fidelity Investments
25
Fidelity Investments
Massachusetts
– -$33 -1 Closed

MBRX Hedge Fund Activity: Q2 2025 in Review

21 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2025, worth a combined $118K — down 92% from $1.44M a quarter earlier.

Fund positioning in MBRX was balanced in Q2 2025: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 0 trimmed.

The largest buyer was Citigroup, adding an estimated $67.6K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.22M sold.

  • 21 institutional investors held Moleculin Biotech (MBRX) as of Q2 2025, down from 22 in Q1 2025.
  • Funds reported $118K of Moleculin Biotech stock for Q2 2025, down 92% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q2 2025 and 4 closed out, a net change of 0 holders.
  • The largest Moleculin Biotech buyer in Q2 2025 was Citigroup, an estimated $67.6K added.
  • The largest Moleculin Biotech seller in Q2 2025 was Armistice Capital, an estimated $1.22M sold.

Based on aggregated 13F filings for Q2 2025.